Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
about
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Phase II study of a triple com ...... tive metastatic breast cancer.
@en
Phase II study of a triple com ...... tive metastatic breast cancer.
@nl
type
label
Phase II study of a triple com ...... tive metastatic breast cancer.
@en
Phase II study of a triple com ...... tive metastatic breast cancer.
@nl
prefLabel
Phase II study of a triple com ...... tive metastatic breast cancer.
@en
Phase II study of a triple com ...... tive metastatic breast cancer.
@nl
P2093
P1433
P1476
Phase II study of a triple com ...... tive metastatic breast cancer.
@en
P2093
Antonio Llombart
Arlene Chan
Françoise Majois
Gustavo Villanova
Lubos Petruzelka
Marc Espie
Miguel Gil Gil
Nathalie Vaissiere
Nicole Tubiana-Mathieu
Pier-Franco Conte
P304
P407
P577
2013-06-01T00:00:00Z